Pfizer will end development of weight-loss pill over fears about its impact to the liver - The drugmaker said the patient’s injury ‘resolved’ after they stopped taking the drug ...

Sanofi’s next-generation experimental asthma drug failed to significantly reduce flare-ups in patients with moderate-to-severe asthma, dimming hopes it could help offset the patent expiry of its ...

In 2024, the FDA's Center for Drug Evaluation and Research (CDER) approved 50 new drugs. The CDER director, Patrizia Cavazzoni, M.D., stepped down in January and joined Pfizer's C-suite as chief ...

BMO Capital Markets analyst Evan Seigerman said Pfizer’s discontinuation of its GLP-1 pill sends the company back to the starting block as its other obesity drugs are all in the early stages of ...

Pfizer is stopping development of its experimental oral GLP-1 drug for obesity, the company announced Monday, after a patient ...

Lepodisiran, a new drug, slashed levels of “stealthy cholesterol”—a hidden heart risk affecting 1 in 5 people—by up to 95% in ...

From STAT’s Matthew Herper: Pfizer said this morning that it would stop development of danuglipron, its experimental oral GLP-1 medicine to treat obesity, focusing its efforts on another medicine with ...

Capping more than two years of stock-gyrating drama, Pfizer said Monday that it would stop development of danuglipron, its ...

Pfizer has discontinued the development of experimental weight-loss pill danuglipron after a trial patient experienced ...

Researchers have discovered an experimental medication that significantly reduces a cholesterol-like particle that can ...

The FDA laid out a three-year roadmap to phase out animal toxicity testing in drug research. In addition to organoids and lab ...

Democratic Kansas Gov. Laura Kelly condemned Republican overreach in health care as she announced Wednesday evening a list of ...